Argus lowers TransMedics stock target to USD 76.00

Published on 10/15/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argus set a USD 76.00 target on October 7, 2026. TransMedics stock stood at EUR 67.08 at Lang & Schwarz on October 15, 2026, with a USD 2.6 billion value.

Growth and calendar details

Argus set a USD 76.00 target for TransMedics on October 7, 2026.
Second-quarter 2026 revenue reached USD 189.9 million, up 21 percent year over year.
TransMedics stock stood at EUR 67.08 at 1:45 p.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter results are estimated for November 4, 2026.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group (US89377M1099) drew a USD 76.00 price target from Argus on October 7, 2026, according to Yahoo Finance. The target reduction puts valuation scrutiny alongside a business that reported USD 189.9 million in second-quarter revenue and raised its 2026 revenue outlook.

Three dates shape the story

On August 4, 2026, TransMedics reported second-quarter revenue of USD 189.9 million, up 21 percent from USD 157.4 million a year earlier, while diluted earnings per share fell to USD 0.41 from USD 0.92, according to MarketWatch. Barclays initiated coverage with a USD 120.00 target on October 6, 2026, and Argus set its USD 76.00 target on October 7, 2026, according to Markets Insider.

What does the guidance imply?

TransMedics raised the low end of its full-year 2026 revenue guidance to USD 737 million from USD 727 million, while keeping the upper end at USD 757 million. The range implies 22 percent to 25 percent growth over 2025, but the company expects adjusted operating margin of 12.5 percent to 14.0 percent excluding PAD Aviation. The second-quarter adjusted operating margin was 13.6 percent, compared with a 12.5 percent GAAP operating margin, as investment in OCS Kidney and other clinical programs increased.

Upcoming dates for investors

MarketBeat estimates the third-quarter 2026 results for November 4, 2026, after the market closes, with a conference call scheduled for October 28, 2026. The calendar gives the next report a concrete test: consensus revenue is USD 178.05 million, against USD 143.82 million in the year-earlier quarter, while consensus earnings per share are USD 0.2976 versus USD 0.66.

Euro quote sets the reference

TransMedics operates in medical devices and uses its Organ Care System to preserve and assess donor organs for heart, lung and liver transplantation. Its cash balance was USD 472.7 million on June 30, 2026, providing financial capacity while the company funds product development and logistics expansion.

The stock was trading at EUR 67.08 at Lang & Schwarz on October 15, 2026 at 1:45 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of TransMedics Group stock.